U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. MannKind Corporation - 578282 - 10/23/2019
  1. Warning Letters

CLOSEOUT LETTER

MannKind Corporation MARCS-CMS 578282 —

Product:
Drugs
Recipient:
Recipient Name
Susanne Steiner
Recipient Title
Associate Director, Regulatory Affairs
MannKind Corporation

30930 Russell Ranch Road, #300
Westlake Village, CA 91362
United States

Issuing Office:
Office of Prescription Drug Promotion

10903 New Hampshire Avenue
Silver Spring, MD 20993
United States

Dear Ms. Steiner:

The Food and Drug Administration has completed evaluation of your firm's corrective actions in response to our Warning Letter dated October 5, 2018. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA surveillance will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during subsequent surveillance or through other means.

If you have any questions or comments, please direct your response to the undersigned at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. To ensure timely delivery of your submissions, please use the full address above and include a prominent directional notation (e.g. a sticker) to indicate that the submission is intended for OPDP. Please refer to MA 439 in addition to the NOA number in all future correspondence relating to this particular matter.

Sincerely,
{See appended electronic signature page}
Ankur Kalola, Pharm.D., RAC
Regulatory Review Officer
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

--------------------------------------------------------------------------------------------
This is a representation of an electronic record that was signed
electronically. Following this are manifestations of any and all
electronic signatures for this electronic record.
--------------------------------------------------------------------------------------------
/s/
ANKUR S KALOLA
10/23/2019 03:34:02 PM

Back to Top